Abbott experimental drug kills leukemia cells

Source: Pharmaceutical Business Review
Date: 20th November 2006

Summary:

Researchers at the University of Texas MD Anderson Cancer Center have found that Abbott Laboratories' experimental drug ABT-737 can destroy acute myeloid leukemia cells. The drug was powerful in its own right, the researchers say, but they found that some acute myeloid (AML) cells were themselves resistant to ABT-737, so they added another drug that knocked out this secondary resistance. Together, these agents may provide a powerful therapy against AML, and could form the basis of a new way to treat the cancer, say the scientists.